For 150 years, scientists have known that glycosylation—the process in which complex sugars
are attached to proteins—can tell us about the development and progression of disease. Yet,
glycosylation's molecular complexity made it nearly impossible to study at scale or apply to our
most urgent clinical needs.
Until now.
InterVenn has developed the first commercially available platform to exponentially improve the speed, scope, and scale of glycoproteomics. Powered by artificial intelligence (AI) and advanced machine learning (ML), GlycoVision™ can do what a human operator would take months to achieve in a matter of minutes.
When it comes to identifying cancer, there’s no such thing as too early. In 2023, InterVenn will release GlycoKnow™ Colon, a laboratory-developed test that uses glycoproteomics to pinpoint precursors to colon cancer with a single blood draw, empowering healthcare professionals to work ahead of the onset of disease.
InterVenn is the brainchild of visionary leaders from disparate fields who have combined their expertise to prime glycoproteomics for modern-day exploration.
Founded by Nobel Laureate Dr Carolyn Bertozzi, world-class scientist and distinguished professor Dr Carlito Lebrilla, and leading AI/ML expert Aldo Carrascoso, InterVenn is united in our collective vision to create a new era of personalized, predictive, and preventive care.
2 Tower Place, 5th Floor,
South San Francisco, CA 94080
Bay Area Lab
